DarioHealth Announces $28.6 Million Private Placement
closed a private placement transaction with accredited investors, including healthcare funds and institutions from the U.S. and Israel
pre-funded warrants to purchase 824,689 shares of common stock at an exercise price of $0.0001 per share. The purchase price per share was equal to $7.47, or the "Minimum Price," pursuant to Nasdaq Rule 5635(d) as of July 28, 2020, and the purchase price of each pre-funded warrant was $7.4699.
The adoption rate of digital therapeutics has been accelerated by the current pandemic.
prnewswire.com/news-releases/dariohealth-announces-28-6-million-private-placement-301103959.html
Twitter:
Ben Rabizadeh
DRIO HUGE bullish raise $29M in financing now positions them to grow rapidly in the 
OTRK 
LVGO 
TDOC telehealth space! 🚀
This was not a bad offering out of desperation but rather a good offering to fuel the increased demand.
Insider buying-sec fillings 4k
closed a private placement transaction with accredited investors, including healthcare funds and institutions from the U.S. and Israel
pre-funded warrants to purchase 824,689 shares of common stock at an exercise price of $0.0001 per share. The purchase price per share was equal to $7.47, or the "Minimum Price," pursuant to Nasdaq Rule 5635(d) as of July 28, 2020, and the purchase price of each pre-funded warrant was $7.4699.
The adoption rate of digital therapeutics has been accelerated by the current pandemic.
prnewswire.com/news-releases/dariohealth-announces-28-6-million-private-placement-301103959.html
Twitter:
Ben Rabizadeh
DRIO HUGE bullish raise $29M in financing now positions them to grow rapidly in the OTRK LVGO TDOC telehealth space! 🚀This was not a bad offering out of desperation but rather a good offering to fuel the increased demand.
Insider buying-sec fillings 4k
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.